BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: Medicare 'doc fix' bill dies in Senate; SGR still in play

Oct. 23, 2009
By Mark McCarty

Monitors an issue for FDA in digital pathology imaging

Oct. 23, 2009
By Mark McCarty
GAITHERSBURG, Maryland – There is no novelty to the assertion that technology drives FDA's regulations, so the fact that FDA would convene a two-day session with the hematology and pathology devices advisory committee to discuss how to reliably employ digital images of pathology slides in diagnostic workups is not a surprise. (Medical Device Daily)
Read More

Washington roundup: Philips said to be clear of issues in warning letter

Oct. 22, 2009
By Mark McCarty

Washington roundup: Baxter snared by FDA warning for changes to manufacturing

Oct. 21, 2009
By Mark McCarty

Washington roundup: FDA reports inter-agency review of QoL for LASIK

Oct. 19, 2009
By Mark McCarty

Washington roundup: Sharfstein: FDA not up for 'old standards' in new er

Oct. 16, 2009
By Mark McCarty

Investors see diagnostics as reliable avenue for returns

Oct. 15, 2009
By Mark McCarty

FDAer: 510(k) 'not a rubber stamp or fast-track' process

Oct. 15, 2009
By Mark McCarty
WASHINGTON — The Advanced Medical Technology Association (AdvaMed; Washington) held a session at its annual meeting titled "Demystifying the 510(k) Process," but the mood at the meeting was that if there's anything cryptic about the process, it's not where the process currently stands; it's where the process is headed. (Medical Device Daily)
Read More

Internal communication still a danger zone in discovery

Oct. 14, 2009
By Mark McCarty

Ubl: $40B tax on industry would be 'devastating'

Oct. 14, 2009
By Mark McCarty
WASHINGTON – The Advanced Medical Technology Association (AdvaMed; Washington) made use of its bully pulpit yesterday in a session during which the association's president and board chairman warned that the $40 billion tax on the device industry as embodied in the bill by the Senate Finance constitutes "a really devastating proposal for a large share of our membership." (Medical Device Daily)
Read More
Previous 1 2 … 495 496 497 498 499 500 501 502 503 … 576 577 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing